Trapidil inhibits monocyte chemoattractant protein-1 and macrophage accumulation after balloon arterial injury in rabbits

Laboratory Investigation

Volumn 79, Issue 11, 1999, Pages 1369-1375

  Poon, Michael ^a   Cohen, Jason ^a   Siddiqui, Zakaria ^a   Fallon, John T ^a   Taubman, Mark B ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCYTE CHEMOTACTIC PROTEIN 1; TRAPIDIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTERY INJURY; ARTERY INTIMA PROLIFERATION; ARTICLE; CELL ADHESION; CELL MIGRATION; CHEMOTAXIS; CONTROLLED STUDY; DRUG EFFECT; FEMORAL ARTERY; HYPERCHOLESTEROLEMIA; MACROPHAGE ACTIVATION; MONOCYTE; MORPHOMETRICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RABBIT;

ANIMALS; BALLOON DILATATION; CELL COUNT; CHEMOKINE CCL2; FEMORAL ARTERY; MACROPHAGES; PLATELET AGGREGATION INHIBITORS; RABBITS; TRAPIDIL; WOUNDS AND INJURIES;

EID: 0032735441     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Beitz J, Kruger J, Beitz A, Pawelski K, Szymanski C, Rath FW, and Mest HJ (1991). Influence of the trapidil derivative AR 12463 on serum and tissue lipids and development of aortic lesions during experimental atherosclerosis in rabbits. Biomed Biochim Acta 50:101-107.
2. Benelli U, Lepri A, Nardi M, Danesi R, and Del Tacca M (1995). Trapidil inhibits endothelial cell proliferation and angiogenesis in the chick chorioallantoic membrane and in the rat cornea. J Ocul Pharmacol Ther 11:157-166.
3. Bonisch D, Weber AA, Wittpoth M, Osinski M, and Schror K (1998). Antimitogenic effects of trapidil in coronary artery smooth muscle cells by direct activation of protein kinase A. MoI Pharmacol 54:241-248.
4. Cathcart MK, Morel DW, and Chisolm GM III (1985). Monocytes and neutrophils oxidize low density lipoprotein making it cytotoxic. J Leukoc Biol 38:341-350.
5. Clinton SK and Libby P (1992). Cytokines and growth factors in atherogenesis. Arch Pathol Lab Med 116:1292-1300.
6. Cochran BH, Reffel AC, and Stiles CD (1983). Molecular cloning of gene sequences regulated by platelet-derived growth factor. Cell 33:939-947.
7. Cross AK, Richardson V, Ali SA, Palmer I, Taub DD, and Rees RC (1997). Migration responses of human monocytic cell lines to alpha- and beta-chemokines. Cytokine 9:521-528.
8. Cushing SD, Berliner JA, Valente AJ, Territo MC, Navab M, Parhami F, Gerrity R, Schwartz CJ, and Fogelman AM (1990). Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci USA 87:5134-5138.
9. Faggiotto A and Ross R (1984). Studies of hypercholesterolemia in the nonhuman primate. II. Fatty streak conversion to fibrous plaque. Arteriosclerosis 4:341-356.
10. Faggiotto A, Ross R, and Harker L (1984). Studies of hypercholesterolemia in the nonhuman primate. I. Changes that lead to fatty streak formation. Arteriosclerosis 4:323-340.
11. Ferns GA, Forster L, Stewart-Lee A, Konneh M, Nourooz-Zadeh J, and Anggard EE (1992). Probucol inhibits neointimal thickening and macrophage accumulation after balloon injury in the cholesterol-fed rabbit. Proc Natl Acad Sci USA 89: 11312-11316.
12. Galassi AR, Tamburino C, Nicosia A, Russo G, Grassi R, Monaco A, and Giuffrida G (1999). A randomized comparison of trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, versus aspirin in prevention of angiographic restenosis after coronary artery Palmaz-Schatz stent implantation. Catheter Cardiovasc Interv 46:162-168.
13. Galis ZS, Sukhova GK, Kranzhofer R, Clark S, and Libby P (1995). Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proc Natl Acad Sci USA 92:402-406.
14. Gerrity RG (1981 a). The role of the monocyte in atherogenesis. I. Transition of blood-borne monocytes into foam cells in fatty lesions. Am J Pathol 103:181-190.
15. Gerrity RG (1981b). The role of the monocyte in atherogenesis. II. Migration of foam cells from atherosclerotic lesions. Am J Pathol 103:191-200.
16. Gertz SD, Gimple LW, Ragosta M, Roberts WC, Haber HL, Powers ER, Perez LS, and Sarembock IJ (1993). Response of femoral arteries of cholesterol-fed rabbits to balloon angioplasty with or without laser: emphasis on the distribution of foam cells. Exp Mol Pathol 59:225-243.
17. Gesualdo L, Di Paolo S, Ranieri E, and Schena FP (1994). Trapidil inhibits human mesangial cell proliferation: Effect on PDGF beta-receptor binding and expression. Kidney Int 46:1002-1009.
18. Hanke H, Hassenstein S, Ulmer A, Kamenz J, Oberhoff M, Haase KK, Baumbach A, Gown AM, and Karsch KR (1994). Accumulation of macrophages in the arterial vessel wall following experimental balloon angioplasty. Eur Heart J 15: 691-698.
19. Hoshiya M and Awazu M (1998). Trapidil inhibits platelet-derived growth factor-stimulated mitogen-activated protein kinase cascade. Hypertension 31:665-671.
20. Klurfeld DM (1985). Identification of foam cells in human atherosclerotic lesions as macrophages using monoclonal antibodies. Arch Pathol Lab Med 109:445-449.
21. Kuratsu J, Sato K, Saitoh Y, Takeshima H, Morioka M, and Ushio Y (1995). The mechanism of growth-regulation of glioma cells by trapidil. J Neurooncol 23:201-206.
22. Libby P, Geng YJ, Aikawa M, Schoenbeck U, Mach F, Clinton SK, Sukhova GK, and Lee RT (1996). Macrophages and atherosclerotic plaque stability. Curr Opin Lipidol 7:330-335.
23. Libby P and Tanaka H (1997). The molecular bases of restenosis. Prog Cardiovasc Dis 40:97-106.
24. Liu MW, Roubin GS, Robinson KA, Black AJ, Hearn JA, Siegel RJ, and King SB III (1990). Trapidil in preventing restenosis after balloon angioplasty in the atherosclerotic rabbit. Circulation 81:1089-1093.
25. Marek JM, Koehler C, Aguirre ML, Westerband A, Gentile AT, Mills JL, and Hunter GC (1998). The histologic characteristics of primary and restenotic carotid plaque. J Surg Res 74:27-33.
26. Maresta A, Balducelli M, Cantini L, Casari A, Chioin R, Fabbri M, Fontanelli A, Monici Preti PA, Repetto S, and De Servi S (1994). Trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, reduces restenosis after percutaneous transluminal coronary angioplasty: Results of the randomized, double-blind STARC study. Studio Trapidil versus Aspirin nella Restenosi Coronarica. Circulation 90:2710-2715.
27. Matsuno H, Stassen JM, Hoylaerts MF, Vermylen J, and Deckmyn H (1995). Fast and reproducible vascular neointima formation in the hamster carotid artery: Effects of trapidil and captopril. Thromb Haemost 74:1591-1596.
28. Metcalf D (1989). The molecular control of cell division, differentiation commitment and maturation in haemopoietic cells. Nature 339:27-30.
29. Miller MD and Krangel MS (1992). The human cytokine I-309 is a monocyte chemoattractant. Proc Natl Acad Sci USA 89:2950-2954.
30. Moreno PR, Bernardi VH, Lopez-Cuellar J, Newell JB, McMellon C, Gold HK, Palacios IF, Fuster V, and Fallon JT (1996). Macrophage infiltration predicts restenosis after coronary intervention in patients with unstable angina. Circulation 94:3098-3102.
31. Nelken NA, Coughlin SR, Gordon D, and Wilcox JN (1991). Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest 88:1121-1127.
32. Nieder J, Claus P, and Augustin W (1995). Effects of trapidil on the PG12 and TXA2 synthesis in human umbilical veins perfused in vitro. Prostaglandins 49:311-318.
33. Ohnishi H, Yamaguchi K, Shimada S, Sato M, Funatc H, Katsuki Y, Dabasaki T, Suzuki Y, Saitoh Y, and Kumagai A (1982). Evidence for ̈response to injurÿ hypothesis. Life Sci 31:2595-2602.
34. Okamoto S, Inden M, Setsuda M, Konishi T, and Nakano T (1992). Effects of trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, in preventing restenosis after percutaneous transluminal coronary angioplasty. Am Heart J 123:1439-1444.
35. Poon M, Hsu WC, Bogadanov VY, and Taubman MB (1996). Secretion of monocyte chemotactic activity by cultured rat aortic smooth muscle cells in response to PDGF is due predominantly to the induction of JE/MCP-1. Am J Pathol 149:307-317.
36. Ross R (1997). Cellular and molecular studies of atherogenesis. Atherosclerosis 131 (Suppl):S3-4.
37. Sarembock IJ, LaVeau PJ, Sigal SL, Timms I, Sussman J, Haudenschild C, and Ezekowitz MD (1989). Influence of inflation pressure and balloon size on the development of intimai hyperplasia after balloon angioplasty: A study in the atherosclerotic rabbit. Circulation 80:1029-1040.
38. Sozzani S, Locati M, Zhou D, Rieppi M, Luini W, Lamorte G, Bianchi G, Polentarutti N, Allavena P, and Mantovani A (1995). Receptors, signal transduction, and spectrum of action of monocyte chemotactic protein-1 and related chemokines. J Leukoc Biol 57:788-794.
39. Takeya M, Yoshimura T, Leonard EJ, and Takahashi K (1993). Detection of monocyte chemoattractant protein-1 in human atherosclerotic lesions by an anti-monocyte chemoattractant protein-1 monoclonal antibody. Hum Pathol 24:534-539.
40. Taub DD, Longo DL, and Murphy WJ (1996). Human interferon-inducible protein-10 induces mononuclear cell infiltration in mice and promotes the migration of human T lymphocytes into the peripheral tissues and human peripheral blood lymphocytes-SCID mice. Blood 87:1423-1431.
41. Taubman MB, Rollins BJ, Poon M, Marmur J, Green RS, Berk BC, and Nadal-Ginard B (1992). JE mRNA accumulates rapidly in aortic injury and in platelet-derived growth factor-stimulated vascular smooth muscle cells. Circ Res 70:314-325.
42. Thiruvikraman SV, Guha A, Roboz J, Taubman MB, Nemerson Y, and Fallon JT (1996). In situ localization of tissue factor in human atherosclerotic plaques by binding of digoxigenin-labeled factors VIIa and X. Lab Invest 75:451-461.
43. Tiell ML, Sussman II, Gordon PB, and Saunders RN (1983). Suppression of fibroblast proliferation in vitro and of myointimal hyperplasia in vivo by the triazolopyrimidine, trapidil. Artery 12:33-50.
44. Ueda M, Becker AE, Fujimoto T, and Tsukada T (1991). The early phenomena of restenosis following percutaneous transluminal coronary angioplasty. Eur Heart J 12:937-945.
45. Uguccioni M, D'Apuzzo M, Loetscher M, Dewald B, and Baggiolini M (1995). Actions of the chemotactic cytokines MCP-1, MCP-2, MCP-3, RANTES, MIP-1 alpha and MIP-1 beta on human monocytes. Eur J Immunol 25:64-68.
46. Wiseman DM, Polverini PJ, Kamp DW, and Leibovich SJ (1988). Transforming growth factor-beta (TGF beta) is chemotactic for human monocytes and induces their expression of angiogenic activity. Biochem Biophys Res Commun 157: 793-800.
47. Yasue H, Ogawa H, Tanaka H, Miyazaki S, Hattori R, Saito M, Ishikawa K, Masuda Y, Yamaguchi T, Motomiya T, and Tamura Y (1999). Effects of aspirin and trapidil on cardiovascular events after acute myocardial infarction. Japanese Antiplatelets Myocardial Infarction Study (JAMIS) Investigators. Am J Cardiol 83:1308-1313.
48. Yla-Herttuala S, Lipton BA, Rosenfeld ME, Sarkioja T, Yoshimura T, Leonard EJ, Witztum JL, and Steinberg D (1991). Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci USA 88:5252-5256.
49. Yoshimura T and Leonard EJ (1990). Secretion by human fibroblasts of monocyte chemoattractant protein-1, the product of gene JE. J Immunol 144:2377-2383.
50. Yu X, Dluz S, Graves DT, Zhang L, Antoniades HN, Hollander W, Prusty S, Valente AJ, Schwartz CJ, and Sonenshein GE (1992). Elevated expression of monocyte chemoattractant protein 1 by vascular smooth muscle cells in hypercholesterolemic primates. Proc Natl Acad Sci USA 89:6953-6957.